Blue Ridge Cancer Care

Clinical research site in Roanoke, Virginia · 2522 COLONIAL AVE SW, ROANOKE, VA 24015-3121 · (540) 343-0055 · Website

Part of Blue Ridge Cancer Care

As of July 2026, 25 paid clinical trials are recruiting at Blue Ridge Cancer Care in Roanoke, Virginia. Active studies at this site cover conditions such as Cancer of the Prostate, Follicular Lymphoma and Gastric Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Blue Ridge Cancer Care (25)

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

for Urothelial Cancer

74 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07421700·Phase 1, Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

for Carcinoma, Renal Cell

109 locations incl. Phoenix

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227415·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

for Intestinal Neoplasms

166 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222800·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for Metastatic Castration-resistant Prostate Neoplasms

53 locations incl. La Jolla

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT07164443·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

for Metastatic Castration Sensitive Prostate Cancer (mCSPC)

122 locations incl. Huntsville

Sponsor: Pfizer

Sex: Male·Age: 18+

Code: NCT07028853·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for Breast Neoplasms

59 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06966700·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

for Colorectal Neoplasms

104 locations incl. Glendale

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT05253651·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

for Breast Cancer

134 locations incl. Daphne

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06966453·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

for Solid Tumors

43 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT03486873·Phase 3·Recruiting·Listed Apr 2018

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

42 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

for Metastatic Castration-resistant Prostate Cancer (mCRPC)

57 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136650·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for Diffuse Large B-Cell Lymphoma

46 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06717347·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

for DLBCL

23 locations incl. Glendale

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05139017·Phase 2, Phase 3·Recruiting·Listed Dec 2021

Apply to this trial

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

for Prostate Cancer

49 locations incl. Phoenix

Sponsor: Merck Sharp & Dohme LLC

Sex: Male·Age: 18+

Code: NCT06925737·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

for Prostate Cancer Metastatic

31 locations incl. Palo Alto

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: All ages

Code: NCT06136624·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

for Follicular Lymphoma

31 locations incl. Birmingham

Sponsor: Celgene

Sex: All·Age: 18+

Code: NCT06911502·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

for Metastatic Urothelial Cancer

27 locations incl. Tucson

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT03547973·Phase 2·Recruiting·Listed Jun 2018

Apply to this trial

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

for Metastatic HER2-positive Breast Cancer

45 locations incl. Phoenix

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06435429·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

for Small Cell Lung Cancer (SCLC)

24 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07226999·Phase 2, Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

for Non-small Cell Lung Cancer

9 locations incl. Birmingham

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07190248·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

for Gastric Cancer

15 locations incl. New Haven

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06731478·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

for Gastrointestinal Cancer

8 locations incl. Aurora

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06596694·Phase 1, Phase 2·Recruiting·Listed Sep 2024

Apply to this trial

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

for Prostate Cancer

24 locations incl. Scottsdale

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18 - 100

Code: NCT05803941·Phase 4·Recruiting·Listed Apr 2023

Apply to this trial

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

for Colorectal Cancer

12 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06428409·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

for Multiple Myeloma

16 locations incl. Tucson

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT05972135·Phase 2·Recruiting·Listed Aug 2023

Apply to this trial

More research sites in Roanoke

Carilion Clinic (30 trials)
Carilion Children's (15 trials)
Carilion Roanoke Memorial Hospital (15 trials)
Fralin Biomedical Research Institute at VTC (12 trials)
Oncology and Hematology Associates of Southwest Virginia (BRCC) (4 trials)
Fralin Biomedical Research Institute (3 trials)
Gastroenterology Consultants of Southwest Virginia (3 trials)
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care (3 trials)
Vistar Eye Center (3 trials)
Akero Clinical Study Site (2 trials)

Explore more

Paid clinical trials in Roanoke, VA · Virginia clinical trials